drugset / Trial / NCT05152004
Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment
RandomizedParallel-groupSingle-blindTreatment
Summary
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection. This study aims to better understand the potential of both hybrid and igh-dose dual therapies in the treatment of H. pylori infection. .
Timeline
- Start
- 2018-09-01
- Primary completion
- 2021-11-30
- Completion
- 2022-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 750 mg | — |
| Subject | Amoxicillin | Other / unclassified | 1 g | — |
| Comparator | Clarithromycin | Small molecule | 500 mg | — |
| Comparator | Metronidazole | Small molecule | 500 mg | — |
| Subject | Rabeprazole | Small molecule | 20 mg | — |